Givosiran sodium
Givlaari (givosiran sodium) is an oligonucleotide pharmaceutical. Givosiran sodium was first approved as Givlaari on 2019-11-20. It has been approved in Europe to treat hepatic porphyrias. Givlaari's patents are valid until 2034-10-03 (FDA).
| Trade Name | Givlaari |
|---|---|
| Common Name | Givosiran sodium |
| Indication | hepatic porphyrias |
| Drug Class |
